Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
82 Leser
Artikel bewerten:
(0)

CIVCO Radiotherapy & Adaptiiv Join Forces to Expand 3D Bolus for Radiotherapy

CORALVILLE, Iowa, April 12, 2018 /PRNewswire/ -- CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, and Adaptiiv (formerly 3D Bolus), the definitive 3D technology platform for radiation therapy, are excited to announce their collaboration in bringing more personalized medical devices to the market. This initiative aligns with the missions of both companies to focus on improving patient outcomes in radiotherapy worldwide.

CIVCO will be distributing Adaptiiv software applications as a turn-key solution that enables 3D printing of patient-specific simple or modulated thickness bolus and high dose rate (HDR) surface brachytherapy applicators. The software application integrates directly with existing treatment planning systems allowing the planning software to calculate the treatment plan and provides the ability to 3D print a patient-specific radiotherapy bolus or applicator. This innovative technique requires less time and replaces the need for hard-to-fit simple bolus and expensive applicators and provides a more comfortable fit for the patient.

"Adaptiiv's solutions truly align with our mission of improving patient outcomes worldwide. The ability to utilize images from the treatment planning system and provide customized three-dimensional bolus and applicators is yet another way we are involved in improving the quality and efficiency of care as well as the patient experience," said Nat Geissel, president of CIVCO Radiotherapy.

"CIVCO and Adaptiiv are aligned in our vision of the importance of personalized health solutions. As the innovators of software that enables clinicians to design and 3D print radiation therapy treatment accessories, our goal is to democratize the delivery of patient-specific treatment. To that end, Adaptiiv is thrilled to partner with CIVCO Radiotherapy. CIVCO's highly professional sales team and international distributors give us global reach and will play a significant role in our efforts to provide our patient-specific solution to the global radiotherapy market," stated Peter Hickey, CEO of Adaptiiv.

About Adaptiiv
Adaptiiv (formerly 3D Bolus Inc.) is the definitive 3D technology platform for radiation oncology. Headquartered in Halifax, Nova Scotia, Canada our technology platform seamlessly integrates into existing procedures to provide an end-to-end solution which facilitates the design and fabrication of personalized medical devices using 3D printing. Adaptiiv, formerly 3D Bolus, is ISO 13485 certified, has received a CE Mark and is pending approval by the FDA for a 510k. Currently in the USA the software is an investigational device limited by Federal law to investigational use.

About CIVCO Radiotherapy
CIVCO Radiotherapy has over 35 years' experience developing, manufacturing and providing high-quality, innovative, patient-centric solutions in radiotherapy. These solutions include: advanced patient immobilization and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products and advanced 6DOF robotic patient positioning. Corporate information is available at www.CivcoRT.com.

For further information, please contact:


Shelli Locklear


Sr. Marketing Manager


CIVCO Radiotherapy


Tel: 319-248-6619


Shelli.Locklear@CivcoRT.com

COPYRIGHT © 2018. CIVCO IS A REGISTERED TRADEMARK OF CIVCO MEDICAL SOLUTIONS.ALL OTHER TRADEMARKS ARE PROPERTY OF THEIR RESPECTIVE OWNERS. ALL PRODUCTS MAY NOT BE LICENSED IN ACCORDANCE WITH CANADIAN LAW. 2018C1386 REV. A

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.